The APAC MRDR has recently enrolled its 3,000th patient, marking a step towards improving understanding and treatment of myeloma across the APAC region.

By tracking patient treatment and their outcomes over time, the registry aims to give researchers and clinicians insight into how treatments perform and the best way to use them.

We’re are very grateful to all the hospitals that have made this possible and look forward to continuing our collaboration.